cidrap.umn6h
Shorter, all-oral drug-resistant TB regimens perform well in real-world setting, study finds
In a study in Belarus and Kazakhstan, 96.3% of patients with drug-resistant TB who received the regimens had successful treatment outcomes.
Bantam Pharmaceutical Announces Activation of First Phase 1 Clinical Trial Site at MD Anderson Cancer Center
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...
Food Allergy Research & Education12h
Food Allergy Nonprofit, FARE Announces ATANIS Biotech AG as the Winner of Phase 2 of its Innovation Award Diagnostic Challenge
The FARE Innovation Award Diagnostic Challenge is made possible through generous support from the Naddisy Foundation, the ...
Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation ...
Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to ...